US6500948B1
(en)
|
1995-12-08 |
2002-12-31 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
|
JP2000502330A
(ja)
*
|
1995-12-08 |
2000-02-29 |
アグロン・ファーマシュウティカルズ・インコーポレーテッド |
メタロプロテイナーゼ阻害薬、それらを含有する薬剤組成物および薬剤としてのそれらの使用、ならびにそれらの製造に有用な方法および中間体
|
US6174915B1
(en)
|
1997-03-25 |
2001-01-16 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
US6008243A
(en)
*
|
1996-10-24 |
1999-12-28 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
|
US5985900A
(en)
*
|
1997-04-01 |
1999-11-16 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
AU7294098A
(en)
*
|
1997-05-09 |
1998-11-27 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
AUPO721997A0
(en)
*
|
1997-06-06 |
1997-07-03 |
Queensland Institute Of Medical Research, The |
Anticancer compounds
|
ES2176913T3
(es)
*
|
1997-08-08 |
2002-12-01 |
Pfizer Prod Inc |
Derivados de acidos arilsulfonilaminohidroxamicos.
|
EP0952148B1
(en)
*
|
1998-04-10 |
2004-05-12 |
Pfizer Products Inc. |
Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives
|
GT199900044A
(es)
*
|
1998-04-10 |
2000-09-14 |
|
Procedimientos para preparar haluros de fenoxifenilsulfonilo.
|
PA8469301A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Procedimientos para la preparacion de acidos hidroxamicos.
|
PA8469601A1
(es)
*
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Procedimiento para alquilar sulfonamidas impedidas estericamente
|
US6358980B1
(en)
|
1999-01-27 |
2002-03-19 |
American Cyanamid Company |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
|
US6326516B1
(en)
|
1999-01-27 |
2001-12-04 |
American Cyanamid Company |
Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
|
US6277885B1
(en)
|
1999-01-27 |
2001-08-21 |
American Cyanamid Company |
Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
|
US6340691B1
(en)
|
1999-01-27 |
2002-01-22 |
American Cyanamid Company |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
|
US6225311B1
(en)
|
1999-01-27 |
2001-05-01 |
American Cyanamid Company |
Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
|
US6946473B2
(en)
|
1999-01-27 |
2005-09-20 |
Wyeth Holdings Corporation |
Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
|
US6762178B2
(en)
|
1999-01-27 |
2004-07-13 |
Wyeth Holdings Corporation |
Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
|
US6753337B2
(en)
|
1999-01-27 |
2004-06-22 |
Wyeth Holdings Corporation |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
|
US6313123B1
(en)
|
1999-01-27 |
2001-11-06 |
American Cyanamid Company |
Acetylenic sulfonamide thiol tace inhibitors
|
US6200996B1
(en)
|
1999-01-27 |
2001-03-13 |
American Cyanamid Company |
Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
|
DK1041072T3
(da)
*
|
1999-03-31 |
2003-11-10 |
Pfizer Prod Inc |
Dioxocyclopentylhydroxamsyrer
|
DE19920907A1
(de)
*
|
1999-05-06 |
2000-11-09 |
Basf Ag |
Verfahren zur Herstellung eines Cyclohexylglycin-Bausteins
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
SE0000382D0
(sv)
|
2000-02-07 |
2000-02-07 |
Astrazeneca Ab |
New process
|
US7141607B1
(en)
|
2000-03-10 |
2006-11-28 |
Insite Vision Incorporated |
Methods and compositions for treating and inhibiting retinal neovascularization
|
US6458822B2
(en)
|
2000-03-13 |
2002-10-01 |
Pfizer Inc. |
2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
|
DZ3494A1
(fr)
|
2001-01-05 |
2002-07-11 |
Pfizer |
Anticorps anti-recepteur du facteur de croissance i analogue a l'insuline
|
AU2002345792A1
(en)
|
2001-06-21 |
2003-01-08 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
CA2464727A1
(en)
|
2001-11-01 |
2003-05-08 |
Wyeth Holdings Corporation |
Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
CA2471814C
(en)
*
|
2001-12-27 |
2011-03-15 |
Sumitomo Pharmaceuticals Co., Ltd. |
Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient
|
JP2005527511A
(ja)
|
2002-03-01 |
2005-09-15 |
ファイザー インコーポレイテッド |
抗血管形成剤として有用なチエノピリジンのインドリル−尿素誘導体およびその使用法
|
EP1485131A1
(en)
*
|
2002-03-08 |
2004-12-15 |
Novartis AG |
Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer
|
KR100984613B1
(ko)
|
2002-03-13 |
2010-09-30 |
어레이 바이오파마 인크. |
Mek 억제제로서의 n3 알킬화 벤즈이미다졸 유도체
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
PT1585743E
(pt)
|
2002-12-19 |
2007-07-12 |
Pfizer |
Compostos de 2- (1h-indazol-6-ilamin)-benzamida como inibidores de proteína-cinases úteis para o tratamento de doenças aftálmicas.
|
AU2003294917A1
(en)
*
|
2002-12-20 |
2004-07-14 |
Novartis Ag |
Device and method for delivering mmp inhibitors
|
US7199155B2
(en)
|
2002-12-23 |
2007-04-03 |
Wyeth Holdings Corporation |
Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
|
EP2476667B1
(en)
|
2003-02-26 |
2014-07-16 |
Sugen, Inc. |
Aminoheteroaryl compounds as protein kinase inhibitors
|
DK1606288T3
(da)
*
|
2003-03-25 |
2009-10-05 |
Fournier Lab Sa |
Benzensulfonamidderivater, fremgangsmåde til fremstilling deraf og deres anvendelse til behandling af smerte
|
DK1656391T3
(da)
|
2003-08-13 |
2011-01-03 |
Pfizer Prod Inc |
Modificerede humane IGF-1R antistoffer
|
ES2314444T3
(es)
|
2003-08-29 |
2009-03-16 |
Pfizer Inc. |
Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos.
|
US7144907B2
(en)
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
MXPA06005657A
(es)
|
2003-11-19 |
2006-08-23 |
Array Biopharma Inc |
Inhibidores heterociclicos de mek y metodos para usarlos.
|
WO2006021884A2
(en)
|
2004-08-26 |
2006-03-02 |
Pfizer Inc. |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
US7429667B2
(en)
|
2005-01-20 |
2008-09-30 |
Ardea Biosciences, Inc. |
Phenylamino isothiazole carboxamidines as MEK inhibitors
|
PL2364973T3
(pl)
|
2005-05-18 |
2014-12-31 |
Array Biopharma Inc |
Heterocykliczne inhibitory MEK i sposoby ich stosowania
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
JP5055284B2
(ja)
|
2005-09-20 |
2012-10-24 |
オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー |
インシュリン様成長因子−1受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
|
TWI405756B
(zh)
|
2005-12-21 |
2013-08-21 |
Array Biopharma Inc |
新穎硫酸氫鹽
|
US7842836B2
(en)
|
2006-04-11 |
2010-11-30 |
Ardea Biosciences |
N-aryl-N'alkyl sulfamides as MEK inhibitors
|
JP5269762B2
(ja)
|
2006-04-18 |
2013-08-21 |
アーディア・バイオサイエンシーズ・インコーポレイテッド |
Mek阻害剤としてのピリドンスルホンアミドおよびピリドンスルファミド
|
EP2121626A1
(en)
|
2006-12-15 |
2009-11-25 |
Pfizer Products Inc. |
Benzimidazole derivatives
|
WO2008089459A1
(en)
|
2007-01-19 |
2008-07-24 |
Ardea Biosciences, Inc. |
Inhibitors of mek
|
CN101678215B
(zh)
|
2007-04-18 |
2014-10-01 |
辉瑞产品公司 |
用于治疗异常细胞生长的磺酰胺衍生物
|
US8530463B2
(en)
|
2007-05-07 |
2013-09-10 |
Hale Biopharma Ventures Llc |
Multimodal particulate formulations
|
UA99731C2
(ru)
|
2007-07-30 |
2012-09-25 |
Ардеа Биосайенсис, Инк |
Кристаллические полиморфные формы n-(ариламино)сульфонамидов как ингибиторы мэк, композиция (варианты) и применение
|
PE20131210A1
(es)
|
2007-12-19 |
2013-10-31 |
Genentech Inc |
Derivados de 5-anilinoimidazopiridina como inhibidores de mek
|
AU2008340247B2
(en)
|
2007-12-21 |
2012-11-15 |
Genentech, Inc. |
Azaindolizines and methods of use
|
MY159955A
(en)
|
2008-01-04 |
2017-02-15 |
Intellikine Inc |
Certain chemical entities, compositions and methods
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
WO2009114870A2
(en)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
AU2009228093B2
(en)
|
2008-03-28 |
2014-08-07 |
Neurelis, Inc. |
Administration of benzodiazepine compositions
|
KR20110039326A
(ko)
|
2008-07-08 |
2011-04-15 |
인텔리카인, 인크. |
키나제 억제제 및 사용 방법
|
EP2334701A4
(en)
|
2008-10-16 |
2014-01-08 |
Univ Pittsburgh |
FULLY HUMAN ANTIBODIES AGAINST ANTIGENES ASSOCIATED WITH MELANOMA OF HIGH MOLECULAR WEIGHT AND USES THEREOF
|
US8476431B2
(en)
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
CN102365021B
(zh)
|
2009-02-05 |
2015-07-15 |
伊缪诺金公司 |
新型苯并二氮杂*衍生物
|
SG172857A1
(en)
|
2009-02-09 |
2011-08-29 |
Supergen Inc |
Pyrrolopyrimidinyl axl kinase inhibitors
|
EP2400985A2
(en)
|
2009-02-25 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
|
JP2012519170A
(ja)
|
2009-02-26 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
生体内の腫瘍細胞のemtステータスをモニターするためのinsitu法
|
JP2012519281A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
WO2010098866A1
(en)
|
2009-02-27 |
2010-09-02 |
Supergen, Inc. |
Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US8465912B2
(en)
|
2009-02-27 |
2013-06-18 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010108652A1
(en)
|
2009-03-27 |
2010-09-30 |
Ardea Biosciences Inc. |
Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors
|
CA2760791C
(en)
|
2009-05-07 |
2017-06-20 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
EP2459191A1
(en)
|
2009-07-31 |
2012-06-06 |
OSI Pharmaceuticals, LLC |
Mtor inhibitor and angiogenesis inhibitor combination therapy
|
MX2012002066A
(es)
|
2009-08-17 |
2012-03-29 |
Intellikine Inc |
Compuestos heterociclicos y usos de los mismos.
|
US20120157471A1
(en)
|
2009-09-01 |
2012-06-21 |
Pfizer Inc. |
Benzimidazole derivatives
|
US9034861B2
(en)
|
2009-10-13 |
2015-05-19 |
Allomek Therapeutics Llc |
MEK inhibitors useful in the treatment of diseases
|
WO2011049625A1
(en)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Method for aflatoxin screening of products
|
CA3022722A1
(en)
|
2009-11-05 |
2011-05-12 |
Rhizen Pharmaceuticals S.A. |
Pi3k protein kinase modulators
|
US9173961B2
(en)
|
2010-02-10 |
2015-11-03 |
Immunogen, Inc. |
CD20 antibodies and uses thereof
|
US8754072B2
(en)
|
2010-02-12 |
2014-06-17 |
Pfizer Inc. |
Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
|
EP2542893A2
(en)
|
2010-03-03 |
2013-01-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
CA2783656A1
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
CN107674073B
(zh)
|
2010-05-17 |
2021-09-10 |
印蔻真治疗公司 |
作为蛋白激酶调节剂的3,5-二取代-3h-咪唑(或[1,2,3]三唑)并[4,5-b] 吡啶化合物
|
US8604032B2
(en)
|
2010-05-21 |
2013-12-10 |
Infinity Pharmaceuticals, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
CN103068851B
(zh)
|
2010-06-16 |
2015-03-11 |
高等教育联邦系统-匹兹堡大学 |
内质蛋白的抗体及其用途
|
CA2813162C
(en)
|
2010-10-20 |
2015-06-16 |
Pfizer Inc. |
Pyridine-2- derivatives as smoothened receptor modulators
|
US8901133B2
(en)
|
2010-11-10 |
2014-12-02 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
KR101875720B1
(ko)
|
2011-01-10 |
2018-07-09 |
인피니티 파마슈티칼스, 인코포레이티드 |
이소퀴놀린온 및 이의 고체 형태의 제조 방법
|
AU2012212075A1
(en)
|
2011-02-02 |
2013-07-18 |
Amgen Inc. |
Methods and compositons relating to inhibition of IGF-1R
|
EP2675479B1
(en)
|
2011-02-15 |
2016-01-13 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
JP5808826B2
(ja)
|
2011-02-23 |
2015-11-10 |
インテリカイン, エルエルシー |
複素環化合物およびその使用
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
EP2699598B1
(en)
|
2011-04-19 |
2019-03-06 |
Pfizer Inc |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
US9896730B2
(en)
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
JP6118314B2
(ja)
|
2011-05-04 |
2017-04-19 |
ライゼン・ファーマシューティカルズ・エスアー |
タンパク質キナーゼのモジュレーターとしての新規化合物
|
EP4085899A1
(en)
|
2011-06-14 |
2022-11-09 |
Neurelis, Inc. |
Administration of benzodiazepine
|
US9056877B2
(en)
|
2011-07-19 |
2015-06-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
JP6027610B2
(ja)
|
2011-07-19 |
2016-11-16 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環式化合物及びその使用
|
EP3409278B8
(en)
|
2011-07-21 |
2020-11-04 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Heterocyclic protein kinase inhibitors
|
EP2751093A1
(en)
|
2011-08-29 |
2014-07-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CN102408411B
(zh)
|
2011-09-19 |
2014-10-22 |
北京康辰药业股份有限公司 |
一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
|
CA2847540C
(en)
|
2011-09-22 |
2016-05-17 |
Pfizer Inc. |
Pyrrolopyrimidine and purine derivatives
|
WO2013049332A1
(en)
|
2011-09-29 |
2013-04-04 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
ES2654160T3
(es)
|
2011-10-04 |
2018-02-12 |
Igem Therapeutics Limited |
Anticuerpos de IgE anti-HMW-MAA
|
US20140286959A1
(en)
|
2011-11-08 |
2014-09-25 |
Pfizer Inc. |
Methods of Treating Inflammatory Disorders Using Anti-M-CSF Antibodies
|
US9452215B2
(en)
|
2012-02-22 |
2016-09-27 |
The Regents Of The University Of Colorado |
Bourvadin derivatives and therapeutic uses thereof
|
WO2013126617A1
(en)
|
2012-02-22 |
2013-08-29 |
The Regents Of The University Of Colorado, A Body Corporate |
Bouvardin derivatives and therapeutic uses thereof
|
EP2831073B1
(en)
|
2012-03-30 |
2020-12-09 |
Rhizen Pharmaceuticals S.A. |
Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of c-met protein kinases
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
AU2013270684B2
(en)
|
2012-06-08 |
2018-04-19 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
EP2863955B1
(en)
|
2012-06-26 |
2016-11-23 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
EP2887965A1
(en)
|
2012-08-22 |
2015-07-01 |
ImmunoGen, Inc. |
Cytotoxic benzodiazepine derivatives
|
EP2890402B1
(en)
|
2012-08-31 |
2019-04-17 |
Sutro Biopharma, Inc. |
Modified amino acids comprising an azido group
|
WO2014062838A2
(en)
|
2012-10-16 |
2014-04-24 |
Tolero Pharmaceuticals, Inc. |
Pkm2 modulators and methods for their use
|
DK2914296T4
(da)
|
2012-11-01 |
2022-01-03 |
Infinity Pharmaceuticals Inc |
Behandling af cancere under anvendelse af PI3-kinase-isoform-modulatorer
|
JP6494533B2
(ja)
|
2013-02-28 |
2019-04-03 |
イミュノジェン・インコーポレーテッド |
細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体
|
WO2014134486A2
(en)
|
2013-02-28 |
2014-09-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
RU2019119893A
(ru)
|
2013-03-14 |
2019-08-09 |
Толеро Фармасьютикалз, Инк. |
Ингибиторы jak2 и alk2 и способы их использования
|
WO2014151147A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
JP6473133B2
(ja)
|
2013-03-15 |
2019-02-20 |
アラクセス ファーマ エルエルシー |
Krasg12cの共有結合性阻害剤
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
EP2970194A1
(en)
|
2013-03-15 |
2016-01-20 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
WO2014143659A1
(en)
|
2013-03-15 |
2014-09-18 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the gtpase k-ras g12c
|
CA2914284A1
(en)
|
2013-05-30 |
2014-12-04 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using pi3 kinase isoform modulators
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
EP3019522B1
(en)
|
2013-07-10 |
2017-12-13 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
WO2015051341A1
(en)
|
2013-10-03 |
2015-04-09 |
Araxes Pharma Llc |
Inhibitors of erk and methods of use
|
UA121104C2
(uk)
|
2013-10-04 |
2020-04-10 |
Інфініті Фармасьютикалз, Інк. |
Гетероциклічні сполуки і їх застосування
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
CA2926328C
(en)
|
2013-10-10 |
2022-11-29 |
Araxes Pharma Llc |
Substituted quinazolinyl and quinolinyl derivatives and pharmaceutical compositions thereof useful as inhibitors of kras g12c
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
WO2015061204A1
(en)
|
2013-10-21 |
2015-04-30 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
CN106232598B
(zh)
|
2014-04-30 |
2020-03-13 |
辉瑞公司 |
环烷基-连接的二杂环衍生物
|
MA40240B1
(fr)
|
2014-06-19 |
2019-03-29 |
Ariad Pharma Inc |
Composés hétéroaryle d'inhibition de la kinase
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
EP3473271B1
(en)
|
2014-07-31 |
2022-07-20 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Human monoclonal antibodies against epha4 and their use
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
ES2826443T3
(es)
|
2014-09-25 |
2021-05-18 |
Araxes Pharma Llc |
Inhibidores de proteínas mutantes KRAS G12C
|
EP3233829B1
(en)
|
2014-12-18 |
2019-08-14 |
Pfizer Inc |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
KR20180005178A
(ko)
|
2015-04-10 |
2018-01-15 |
아락세스 파마 엘엘씨 |
치환된 퀴나졸린 화합물 및 이의 사용방법
|
WO2016168540A1
(en)
|
2015-04-15 |
2016-10-20 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of kras and methods of use thereof
|
AU2016252609B2
(en)
|
2015-04-20 |
2022-06-30 |
Sumitomo Pharma Oncology, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
CA2984421C
(en)
|
2015-05-01 |
2024-04-09 |
Cocrystal Pharma, Inc. |
Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
|
DK3527574T3
(da)
|
2015-05-18 |
2022-06-27 |
Sumitomo Pharma Oncology Inc |
Alvocidib-prodrugs, der har øget biotilgængelighed
|
TWI703150B
(zh)
|
2015-06-04 |
2020-09-01 |
美商庫拉腫瘤技術股份有限公司 |
用於抑制menin及mll蛋白之交互作用的方法及組合物
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
BR112018002427A8
(pt)
|
2015-08-03 |
2022-10-18 |
Tolero Pharmaceuticals Inc |
Uso de alvocidib e de azacitidina ou decitabina para tratar câncer e kit e composição farmacêutica contendo as ditas substâncias
|
US10689356B2
(en)
|
2015-09-28 |
2020-06-23 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058805A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058807A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
EP3364977A4
(en)
|
2015-10-19 |
2019-09-04 |
Araxes Pharma LLC |
PROCESS FOR SCREENING INHIBITORS OF RAS
|
TW201726656A
(zh)
|
2015-11-16 |
2017-08-01 |
亞瑞克西斯製藥公司 |
包含經取代雜環基團之2-經取代喹唑啉化合物及其使用方法
|
CN108601752A
(zh)
|
2015-12-03 |
2018-09-28 |
安吉奥斯医药品有限公司 |
用于治疗mtap缺失型癌症的mat2a抑制剂
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
WO2017132617A1
(en)
|
2016-01-27 |
2017-08-03 |
Sutro Biopharma, Inc. |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
AU2017235462B2
(en)
|
2016-03-16 |
2021-07-01 |
Kura Oncology, Inc. |
Bridged bicyclic inhibitors of menin-MLL and methods of use
|
CA3015847C
(en)
|
2016-03-16 |
2024-06-11 |
Kura Oncology, Inc. |
Substituted inhibitors of menin-mll and methods of use
|
WO2017172979A1
(en)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
US11883381B2
(en)
|
2016-05-12 |
2024-01-30 |
The Regents Of The University Of Michigan |
ASH1L inhibitors and methods of treatment therewith
|
US11118233B2
(en)
|
2016-05-18 |
2021-09-14 |
The University Of Chicago |
BTK mutation and ibrutinib resistance
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
AU2017321973B2
(en)
|
2016-09-02 |
2024-09-05 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating B cell disorders
|
EP3519402A1
(en)
|
2016-09-29 |
2019-08-07 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
JP2019534260A
(ja)
|
2016-10-07 |
2019-11-28 |
アラクセス ファーマ エルエルシー |
Rasの阻害剤としての複素環式化合物およびその使用方法
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
JP6619519B2
(ja)
|
2016-12-19 |
2019-12-11 |
トレロ ファーマシューティカルズ, インコーポレイテッド |
プロファイリングペプチドおよび感受性プロファイリングのための方法
|
SG10201913491PA
(en)
|
2016-12-22 |
2020-03-30 |
Amgen Inc |
Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
|
JP2020505395A
(ja)
|
2017-01-26 |
2020-02-20 |
アラクセス ファーマ エルエルシー |
縮合n−複素環式化合物およびその使用方法
|
CN110382482A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的杂-杂二环化合物及其使用方法
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
WO2018140512A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
EP3573964A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
WO2018140514A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
JP7117311B2
(ja)
|
2017-01-26 |
2022-08-12 |
ゼットリップ ホールディング リミテッド |
Cd47抗原結合単位およびその使用
|
CN110691779B
(zh)
|
2017-03-24 |
2023-10-10 |
库拉肿瘤学公司 |
治疗血液系统恶性肿瘤和尤因肉瘤的方法
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
US10736897B2
(en)
|
2017-05-25 |
2020-08-11 |
Araxes Pharma Llc |
Compounds and methods of use thereof for treatment of cancer
|
CN110831933A
(zh)
|
2017-05-25 |
2020-02-21 |
亚瑞克西斯制药公司 |
喹唑啉衍生物作为突变kras、hras或nras的调节剂
|
KR20200010306A
(ko)
|
2017-05-25 |
2020-01-30 |
아락세스 파마 엘엘씨 |
Kras의 공유적 억제제
|
US11542248B2
(en)
|
2017-06-08 |
2023-01-03 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with MLL proteins
|
US20200207859A1
(en)
|
2017-07-26 |
2020-07-02 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
WO2019051291A1
(en)
|
2017-09-08 |
2019-03-14 |
Amgen Inc. |
KRAS G12C INHIBITORS AND METHODS OF USE
|
US11497756B2
(en)
|
2017-09-12 |
2022-11-15 |
Sumitomo Pharma Oncology, Inc. |
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
|
BR112020005212A2
(pt)
|
2017-09-18 |
2020-09-15 |
Sutro Biopharma, Inc. |
conjugado de anticorpo, kit, composição farmacêutica, e, métodos de tratamento ou prevenção e de diagnóstico de uma doença ou condição.
|
US11649251B2
(en)
|
2017-09-20 |
2023-05-16 |
Kura Oncology, Inc. |
Substituted inhibitors of menin-MLL and methods of use
|
WO2019075367A1
(en)
|
2017-10-13 |
2019-04-18 |
Tolero Pharmaceuticals, Inc. |
PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
|
EP3706736A4
(en)
|
2017-11-10 |
2021-08-11 |
The Regents of the University of Michigan |
ASH1L DEGRADATION AGENTS AND METHODS OF TREATMENT THROUGH THEM
|
EP3720439A4
(en)
|
2017-12-07 |
2021-09-08 |
The Regents Of The University Of Michigan |
NSD FAMILY INHIBITORS AND TREATMENT METHODS INCLUDING THESE
|
CA3096984A1
(en)
|
2018-04-05 |
2019-10-10 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Axl kinase inhibitors and use of the same
|
EP3788053B1
(en)
|
2018-05-04 |
2024-07-10 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
MA52501A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
CA3099045A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
ES2938987T3
(es)
|
2018-06-01 |
2023-04-18 |
Amgen Inc |
Inhibidores de KRAS G12c y métodos de uso de los mismos
|
EP4155293A1
(en)
|
2018-06-07 |
2023-03-29 |
The Regents of The University of Michigan |
Prc1 inhibitors and methods of treatment therewith
|
MA52780A
(fr)
|
2018-06-11 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
CA3100390A1
(en)
|
2018-06-12 |
2020-03-12 |
Amgen Inc. |
Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
|
MX2021000977A
(es)
|
2018-07-26 |
2021-04-12 |
Sumitomo Pharma Oncology Inc |
Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
|
EP3829580A1
(en)
|
2018-08-01 |
2021-06-09 |
Araxes Pharma LLC |
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
|
EP3852811A1
(en)
|
2018-09-17 |
2021-07-28 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
CA3117210A1
(en)
|
2018-10-24 |
2020-04-30 |
Araxes Pharma Llc |
2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1h-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of g12c mutant kras protein for inhibiting tumor metastasis
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
WO2020106640A1
(en)
|
2018-11-19 |
2020-05-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
WO2020113071A1
(en)
|
2018-11-29 |
2020-06-04 |
Araxes Pharma Llc |
Compounds and methods of use thereof for treatment of cancer
|
JP2022511029A
(ja)
|
2018-12-04 |
2022-01-28 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
がんの処置のための薬剤としての使用のためのcdk9インヒビターおよびその多形
|
MA54546A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
|
EA202191730A1
(ru)
|
2018-12-20 |
2021-08-24 |
Эмджен Инк. |
Ингибиторы kif18a
|
JP2022514268A
(ja)
|
2018-12-20 |
2022-02-10 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤
|
US20220002311A1
(en)
|
2018-12-20 |
2022-01-06 |
Amgen Inc. |
Kif18a inhibitors
|
CA3127502A1
(en)
|
2019-02-12 |
2020-08-20 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
CN113767100A
(zh)
|
2019-03-01 |
2021-12-07 |
锐新医药公司 |
双环杂芳基化合物及其用途
|
US20230096028A1
(en)
|
2019-03-01 |
2023-03-30 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
KR20210141621A
(ko)
|
2019-03-22 |
2021-11-23 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Pkm2 조정제를 포함하는 조성물 및 그를 사용한 치료 방법
|
EP3962951A1
(en)
|
2019-05-03 |
2022-03-09 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
CA3225293A1
(en)
|
2019-05-21 |
2020-11-26 |
Amgen Inc. |
Solid state forms
|
CN114302878A
(zh)
|
2019-07-03 |
2022-04-08 |
大日本住友制药肿瘤公司 |
酪氨酸激酶非受体1(tnk1)抑制剂及其用途
|
MX2022001302A
(es)
|
2019-08-02 |
2022-03-02 |
Amgen Inc |
Inhibidores de kif18a.
|
US20220281843A1
(en)
|
2019-08-02 |
2022-09-08 |
Amgen Inc. |
Kif18a inhibitors
|
US20220289724A1
(en)
|
2019-08-02 |
2022-09-15 |
Amgen Inc. |
Kif18a inhibitors
|
WO2021026099A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
US20220402916A1
(en)
|
2019-09-18 |
2022-12-22 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
TW202126636A
(zh)
|
2019-09-30 |
2021-07-16 |
美商阿吉歐斯製藥公司 |
作為menin抑制劑之六氫吡啶化合物
|
JP2022552873A
(ja)
|
2019-10-24 |
2022-12-20 |
アムジエン・インコーポレーテツド |
がんの治療におけるkras g12c及びkras g12d阻害剤として有用なピリドピリミジン誘導体
|
CR20220230A
(es)
|
2019-10-28 |
2022-06-15 |
Merck Sharp & Dohme |
Inhibidores de pequeñas moléculas de mutante g12c de kras
|
US20230023023A1
(en)
|
2019-10-31 |
2023-01-26 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
TW202132315A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ras 抑制劑
|
CR20220241A
(es)
|
2019-11-04 |
2022-08-03 |
Revolution Medicines Inc |
Inhibidores de ras
|
WO2021091956A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
KR20220100903A
(ko)
|
2019-11-08 |
2022-07-18 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로아릴 화합물 및 이의 용도
|
CA3158188A1
(en)
|
2019-11-14 |
2021-05-20 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
MX2022005726A
(es)
|
2019-11-14 |
2022-06-09 |
Amgen Inc |
Sintesis mejorada del compuesto inhibidor de g12c de kras.
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
BR112022010086A2
(pt)
|
2020-01-07 |
2022-09-06 |
Revolution Medicines Inc |
Dosagem do inibidor de shp2 e métodos de tratamento de câncer
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
EP4114852A1
(en)
|
2020-03-03 |
2023-01-11 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
TW202204333A
(zh)
|
2020-04-08 |
2022-02-01 |
美商阿吉歐斯製藥公司 |
Menin抑制劑及治療癌症之使用方法
|
WO2021207310A1
(en)
|
2020-04-08 |
2021-10-14 |
Agios Pharmaceuticals, Inc. |
Menin inhibitors and methods of use for treating cancer
|
WO2021215545A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
WO2021215544A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
WO2021257736A1
(en)
|
2020-06-18 |
2021-12-23 |
Revolution Medicines, Inc. |
Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
|
JP2023533982A
(ja)
|
2020-07-10 |
2023-08-07 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
Gas41阻害剤及びその使用方法
|
TW202216151A
(zh)
|
2020-07-15 |
2022-05-01 |
日商大鵬藥品工業股份有限公司 |
含有使用於腫瘤之治療之嘧啶化合物之組合
|
AU2021344830A1
(en)
|
2020-09-03 |
2023-04-06 |
Revolution Medicines, Inc. |
Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
|
PE20231207A1
(es)
|
2020-09-15 |
2023-08-17 |
Revolution Medicines Inc |
Derivados indolicos como inhibidores de ras en el tratamiento del cancer
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
AU2021409816A1
(en)
|
2020-12-22 |
2023-07-06 |
Qilu Regor Therapeutics Inc. |
Sos1 inhibitors and uses thereof
|
EP4323356A1
(en)
|
2021-04-13 |
2024-02-21 |
Nuvalent, Inc. |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
EP4329818A1
(en)
|
2021-04-30 |
2024-03-06 |
Celgene Corporation |
Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamma secretase inhibitor (gsi)
|
AR125787A1
(es)
|
2021-05-05 |
2023-08-16 |
Revolution Medicines Inc |
Inhibidores de ras
|
CR20230570A
(es)
|
2021-05-05 |
2024-01-22 |
Revolution Medicines Inc |
Inhibidores de ras
|
JP2024516450A
(ja)
|
2021-05-05 |
2024-04-15 |
レボリューション メディシンズ インコーポレイテッド |
共有結合性ras阻害剤及びその使用
|
US20240317759A1
(en)
|
2021-05-28 |
2024-09-26 |
Taiho Pharmaceutical Co., Ltd. |
Small molecule inhibitors of kras mutated proteins
|
WO2023056589A1
(en)
|
2021-10-08 |
2023-04-13 |
Servier Pharmaceuticals Llc |
Menin inhibitors and methods of use for treating cancer
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
TW202412755A
(zh)
|
2022-04-25 |
2024-04-01 |
美商耐斯泰德醫療公司 |
促分裂原活化蛋白激酶(mek)抑制劑
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
TW202408589A
(zh)
|
2022-06-30 |
2024-03-01 |
美商舒卓生物製藥公司 |
抗ror1抗體及抗體結合物、包含抗ror1抗體或抗體結合物之組合物,及製造及使用抗ror1抗體及抗體結合物之方法
|
AR129187A1
(es)
|
2022-07-08 |
2024-07-24 |
Nested Therapeutics Inc |
Inhibidores de proteína quinasas activadas por mitógeno (mek)
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
WO2024206858A1
(en)
|
2023-03-30 |
2024-10-03 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|